Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Home-Based program aims to help long COVID patients breathe easier and move more

NCT ID NCT07661862

Disease control Sponsor: University of Tasmania Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a comprehensive, remotely delivered care program for people aged 40 and older with Long COVID who have ongoing heart or lung symptoms like fatigue, shortness of breath, or chest pain. The program includes medication review, mental health support, telehealth coaching, and a personalized 24-week exercise plan using a wearable sensor. Researchers measure whether participants can walk farther after 6 months, along with changes in quality of life, mental health, and heart function over two years.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
remote care program (medication review, mental health support, telehealth coaching, and personalized exercise program)
What this could lead to
If successful, this could provide a scalable, home-based care model to improve fitness and quality of life for people with Long COVID-related heart and lung issues.
What could go wrong
This is a single-arm study without a control group, so improvements may be due to natural recovery or other factors. The remote delivery may not suit everyone, and results may not apply to all Long COVID patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 577 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Apr 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged forty years or older * Impaired estimated functional capacity using DASI as proxy (defined by age-normative metabolic equivalent of tasks \[METs\]) * History of COVID-19 (stratified by hospital admission) * Currently symptomatic with fatigue, dyspnoea or chest pain symptoms * Medicare eligibility * Ability and willingness to provide written informed consent to participate in the study. The patient will need to be able to communicate fluently with the investigator. The investigator will need to be satisfied that the patient understands the study by having them explain the study plan back to the investigator. Exclusion Criteria: * Unable to provide written informed consent to participate in this study * Participating in another research trial where randomized treatment would be unacceptable * Mobility impairment that would impact participants' ability to perform exercise * History of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) * Known valvular stenosis or regurgitation of \>moderate severity, history of previous heart failure (baseline New York Heart Association \[NYHA\] \>2) * Oncologic (or other) life expectancy \<12 months or any other medical condition (including pregnancy) that results in the belief (deemed by the Chief Investigators) that it is not appropriate for the patient to participate in this trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Long COVID are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

long COVID-19 Motor Activity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Long COVID

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Baker Heart and Diabetes Institute

    NOT_YET_RECRUITING

    Melbourne, Victoria, 3004, Australia

  • Menzies Insititute for Medical Research

    RECRUITING

    Hobart, Tasmania, 7009, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.